NovaBridge Biosciences - American Depositary Shares (NBP)
NBP moved a median of -1.23% 30 minutes after news, and -2.10% by the close. How NBP actually reacts to news — the realized, point-in-time move the market made, measured across 109 labeled events over the last three years with zero look-ahead.
NBP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.29% | 37% | 107 |
| 30-min | -1.23% | 33% | 107 |
| 60-min | -0.77% | 47% | 107 |
| to close | -2.10% | 34% | 107 |
| Middle 50% of NBP reactions | -2.54% to +0.81% |
|---|---|
| Median reaction (30-min) | -1.23% |
| Measured reactions | 109 |
Half of all NovaBridge Biosciences - American Depositary Shares news events land between -2.54% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NBP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NBP's baseline. Nothing else.
Recent NBP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia | Press release | GlobeNewswire | +1.53% | — | |
| Form 6-K NovaBridge Biosciences For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | -0.83% | -3.01% | |
| Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China | Press release | PR Newswire | -0.83% | -3.01% | |
| Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis | Press release | GlobeNewswire | -0.83% | -3.01% | |
| NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 | Press release | GlobeNewswire | +0.00% | +1.09% | |
| Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight | Press release | PR Newswire | -0.62% | +0.00% | |
| Form 6-K NovaBridge Biosciences For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -2.23% | -0.56% | |
| NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director | Press release | GlobeNewswire | -2.23% | -0.56% | |
| NovaBridge Biosciences to Participate in September Investor Conferences | Press release | GlobeNewswire | -2.60% | -1.56% | |
| Form 6-K NovaBridge Biosciences For: Aug 20 | SEC filing · Form 6-K | SEC EDGAR | -7.36% | -3.05% | |
| Form 6-K NovaBridge Biosciences For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -7.36% | -3.05% | |
| NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution | Press release | GlobeNewswire | -7.36% | -3.05% | |
| Form S-8 NovaBridge Biosciences | SEC filing · Form S-8 | SEC EDGAR | +0.99% | +0.52% | |
| NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026 | Press release | GlobeNewswire | -4.17% | +2.08% | |
| Form 6-K NovaBridge Biosciences For: Jul 24 | SEC filing · Form 6-K | SEC EDGAR | +2.26% | +0.56% | |
| NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 | Press release | GlobeNewswire | +2.26% | +0.56% | |
| Form 6-K NovaBridge Biosciences For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.14% | |
| Form 6-K NovaBridge Biosciences For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | +0.65% | +17.16% | |
| NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer | Press release | GlobeNewswire | +0.65% | +17.16% | |
| Form 20-F/A NovaBridge Biosciences For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -2.27% | +1.95% | |
| Form 6-K NovaBridge Biosciences For: Jun 16 | SEC filing · Form 6-K | SEC EDGAR | -1.82% | -6.21% | |
| NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer | Press release | GlobeNewswire | -1.82% | -6.21% | |
| NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -1.87% | +0.00% | |
| NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference | Press release | GlobeNewswire | -1.42% | -2.37% | |
| Form 6-K NovaBridge Biosciences For: Apr 22 | SEC filing · Form 6-K | SEC EDGAR | +0.39% | -0.77% | |
| NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value | Press release | GlobeNewswire | +0.39% | -0.77% | |
| Form 20-F NovaBridge Biosciences For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.76% | -6.49% | |
| Form 6-K NovaBridge Biosciences For: Apr 07 | SEC filing · Form 6-K | SEC EDGAR | +0.76% | -6.49% | |
| NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.76% | -6.49% | |
| Form 6-K NovaBridge Biosciences For: Mar 16 | SEC filing · Form 6-K | SEC EDGAR | -1.64% | -4.92% | |
| NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer | Press release | GlobeNewswire | -1.64% | -4.92% | |
| Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study | Press release | PR Newswire | +2.38% | -3.74% | |
| Form 6-K NovaBridge Biosciences For: Mar 09 | SEC filing · Form 6-K | SEC EDGAR | -0.29% | +3.09% | |
| NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study | Press release | GlobeNewswire | -0.29% | +3.09% | |
| Form 6-K NovaBridge Biosciences For: Mar 03 | SEC filing · Form 6-K | SEC EDGAR | +1.51% | -3.61% | |
| NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 | Press release | GlobeNewswire | +1.51% | -3.61% | |
| NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | -0.61% | +6.15% | |
| Form 6-K NovaBridge Biosciences For: Feb 25 | SEC filing · Form 6-K | SEC EDGAR | +2.74% | +0.00% | |
| Form 6-K NovaBridge Biosciences For: Feb 19 | SEC filing · Form 6-K | SEC EDGAR | +0.31% | +3.11% | |
| NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | Press release | GlobeNewswire | +0.31% | +3.11% | |
| Form 6-K NovaBridge Biosciences For: Feb 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.23% | |
| NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer | Press release | GlobeNewswire | +0.00% | +1.23% | |
| Form 6-K NovaBridge Biosciences For: Feb 06 | SEC filing · Form 6-K | SEC EDGAR | +2.05% | +6.02% | |
| Form 6-K/A NovaBridge Biosciences For: Feb 06 | SEC filing · Form 6-K | SEC EDGAR | -1.39% | -3.61% | |
| Form 6-K NovaBridge Biosciences For: Jan 22 | SEC filing · Form 6-K | SEC EDGAR | +0.79% | +2.64% | |
| NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei | Press release | GlobeNewswire | +1.07% | +4.81% | |
| Form 6-K NovaBridge Biosciences For: Jan 16 | SEC filing · Form 6-K | SEC EDGAR | +1.07% | +4.81% | |
| Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | -2.47% | -3.29% | |
| Form 6-K NovaBridge Biosciences For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | -8.19% | -24.37% | |
| NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer | Press release | GlobeNewswire | -8.19% | -24.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NBP section they belong to.
Where else NBP is measured.
NBP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NovaBridge Biosciences - American Depositary Shares's median reaction calculated?
Every labeled NBP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 109 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of NBP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NBP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.